mdl 73404 has been researched along with cv 3611 in 1 studies
| Studies (mdl 73404) | Trials (mdl 73404) | Recent Studies (post-2010) (mdl 73404) | Studies (cv 3611) | Trials (cv 3611) | Recent Studies (post-2010) (cv 3611) |
|---|---|---|---|---|---|
| 20 | 0 | 0 | 5 | 0 | 0 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bolkenius, FN; Grisar, JM; Marciniak, G; Verne-Mismer, J; Wagner, ER | 1 |
1 other study(ies) available for mdl 73404 and cv 3611
| Article | Year |
|---|---|
Cardioselective ammonium, phosphonium, and sulfonium analogues of alpha-tocopherol and ascorbic acid that inhibit in vitro and ex vivo lipid peroxidation and scavenge superoxide radicals.
Topics: Adrenergic beta-Antagonists; Animals; Ascorbic Acid; Brain; Free Radical Scavengers; Lipid Peroxidation; Mice; Organophosphorus Compounds; Quaternary Ammonium Compounds; Rats; Stereoisomerism; Sulfonium Compounds; Superoxides; Vitamin E | 1995 |